The Oncologist

Submit to our special series on Clinical Cancer Epidemiology & Real-World Evidence to help advance oncology care across prevention, diagnosis, treatment, and survivorship. 👉Learn more and submit your research: academic.oup.com/oncolo/pages/c… @susanebates @gbanna74 @PasRescigno

Temozolomide reconsidered: Real-world evidence in resistant melanoma cases #MelanomaAwareness @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

An interview with Dr. Francesco Schettini, winner of The Oncologist 2024 Early Career Investigator Award: academic.oup.com/oncolo/pages/e… @susanebates @gbanna74 @PasRescigno

Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Letter to the Editor: Tumor growth rate as an intermediate trial endpoint: doi.org/10.1093/oncolo… RE: doi.org/10.1093/oncolo… @susanebates @gbanna74 @PasRescigno

The Oncologist May 2026 issue: @OxfordJournals: academic.oup.com/oncolo/issue/3… #OpenAccess

Real-world data showing that patients with refractory solid tumors receiving treatment matched to MTB recommendations had ⬆️OS and PFS, supporting the clinical impact of precision MTB-guided therapy. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Can patients, their informal care partners, & their oncologists recall health care contact days over past 1-2 weeks? Yes, fairly accurately! More work needed to develop this simple contact days recall PRO. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

What is the 2L best option after Gem-NabP for patients with metastatic PDAC? Study shows how Interpretable AI outperforms uniform strategies, patient subgroups that truly benefit from Nal-IRI. #PancreaticCancer #AI @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

S-1 vs UFT in rectal cancer ✅S-1 improves RFS ✅Net Treatment Benefit provides a nuanced view on benefit-risk balance ⚠️Age matters: benefit <70 yr, no sig diff ≥70 yr ➡️Pt-centric benefit-risk assessment matters! @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

This real-life study provides additional insight into the use of anti-EGFR and anti-PD1 combination therapy in a later-line setting. #skincancer #immunotherapy #cSCC #reallife @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Multi-center study on clival metastases in prostate cancer 🧬 A unique molecular profile enriched for BRAF & CHEK2 alterations was identified, suggesting potential vulnerabilities to PARP & MAPK inhibitors. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

• Use of LLMs by professionals is ~4x higher than in patients in radiation oncology. • Most HCPs expect patient reliance on LLMs; few patients agree. • Patients express greater trust in physicians compared to LLMs. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Review of recent advances in MUP research, with a focused discussion on its pathogenesis, molecular characteristics, and treatment strategies. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Routine labs predict outcomes in patients with metastatic uveal melanoma receiving hepatic arterial infusion chemotherapy. LDH, GGT, ALT & albumin guide risk-adapted therapy. #AIinMedicine @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Meta-analysis supports #ALND omission in select early BC patients, but survival benefit seen with ALND in mastectomy & advanced T-stage (T3-T4) patients. Personalized decisions vital. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…